Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit You

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
BMC Research Notes|July 5, 2015
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methodsAurélie Bourmaud, Emilie Henin, Fabien Tinquaut, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Gynecologic Oncology|February 6, 2026
Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort studySarah Hodent, Naoual Bakrin, Pascal Rousset, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2023
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trialAlicja Puszkiel, Benoit You, Léa Payen, et al.
Cancers|January 11, 2022
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative ReviewAmbroise Lauby, Olivier Colomban, Pauline Corbaux, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2018
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patientsOlivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2023
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumorsRomain Varnier, Alicja Puszkiel, Michel Tod, et al.
The American Journal of Surgical Pathology|November 19, 2025
Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic VariantsAlexis Trecourt, Clémence Scard, Françoise Descotes, et al.
BMC Pharmacology & Toxicology|January 15, 2014
Hypersensitivity to oxaliplatin: clinical features and risk factorsMarie Parel, Florence Ranchon, Audrey Nosbaum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01Hyun-Woong Cho, Suk-Joon Chang, Myong Cheol Lim, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
BMC Research Notes|July 5, 2015
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methodsAurélie Bourmaud, Emilie Henin, Fabien Tinquaut, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Gynecologic Oncology|February 6, 2026
Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort studySarah Hodent, Naoual Bakrin, Pascal Rousset, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2023
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trialAlicja Puszkiel, Benoit You, Léa Payen, et al.
Cancers|January 11, 2022
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative ReviewAmbroise Lauby, Olivier Colomban, Pauline Corbaux, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2018
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patientsOlivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2023
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumorsRomain Varnier, Alicja Puszkiel, Michel Tod, et al.
The American Journal of Surgical Pathology|November 19, 2025
Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic VariantsAlexis Trecourt, Clémence Scard, Françoise Descotes, et al.
BMC Pharmacology & Toxicology|January 15, 2014
Hypersensitivity to oxaliplatin: clinical features and risk factorsMarie Parel, Florence Ranchon, Audrey Nosbaum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01Hyun-Woong Cho, Suk-Joon Chang, Myong Cheol Lim, et al.
Pageof 15